Primary Prevention Through Risk Prediction Improvement of Major Cardiovascular Events Using POCUS: PRIME POCUS – A Pilot Study

Marie-France Hétu, PhD MSc1; Taylor Barwell, PhD MSc1; Amrita Pannu, MHPE MBBS1; Nilah Ahimsadasan, BMSc1; Tina Zhu, MD FRCPC2,3; Margaret Cases, MD FRCPC3; Sean C. Haffey, MD MSc CCFP(AM)4; Ian Thomson, MSc MD CCFP (SEM)4; Shayna Watson, MEd MD CCFP FCFP4; Taleen Sahakian1; Ulf Näslund, MD PhD5; Amer M. Johri, MD MSc FRCPC FASE1*

(1) Department of Medicine, Division of Cardiology, CINQ, Queen’s University, Kingston, ON, Canada

(2) Department of Medicine, Queen’s University, Kingston, ON, Canada

(3) APEX Heart Centre, Kingston, ON, Canada

(4) Department of Family Medicine, Queen’s Family Health Team, Queen’s University, Kingston, ON, Canada

(5) Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden

*Corresponding Author: Dr. Amer Johri (email: amerschedule@gmail.com)


Download article PDF – POCUS Journal 2026;11(2):96-105

DOI: https://doi.org/10.24908/pocusj.v11i02.20477

Supplementary Material: S1


Abstract

Background: Early screening and treatment of subclinical atherosclerosis is key to preventing myocardial infarction, stroke, and cardiovascular (CV) morbidity and mortality. Carotid point of care ultrasound (POCUS) can be quickly learned by non-conventional ultrasound users and has the potential to be a rapid, safe, inexpensive, and powerful CV risk prediction tool in primary care settings. The goal of this study was to determine the feasibility of training primary healthcare providers (HCPs) in carotid POCUS for CV risk stratification. Methods: This was a prospective two-site study. HCPs completed a 45-minute online training module and a 1-hour expert-led workshop on carotid POCUS and the Rotterdam plaque score. HCPs performed POCUS on their patients who were statin naïve, ≥40 years, with ≥1 cardiac risk factor. Scans were reviewed by an expert to determine the intraclass correlation coefficient (ICC). Treating physicians were surveyed on CV risk reclassification following POCUS results. Results: Five HCPs were enrolled and performed a minimum of 15 carotid POCUS assessments each. The average ICC for the five HCPs was 0.764 (good agreement). Of the 77 patients scanned, plaque score ≥2 (higher risk) was observed in 26 (34%). Changes in treating physician behaviour occurred for 27 patients (35%), where 20 (26%) were reclassified as higher risk, prompting statin initiation. Conclusions: Training community clinic HCPs in carotid POCUS for plaque detection was successful. POCUS influenced patient risk assessment and early statin therapy initiation. Establishing vascular POCUS guidelines and training strategies for non-traditional users is crucial for developing CV screening programs and advancing personalized care.

Introduction

Atherosclerotic cardiovascular disease (ASCVD) imposes an immense burden on both health outcomes and economic resources worldwide [1,2]. A catastrophic but common presentation of ASCVD is a first-time myocardial infarction or stroke in a patient with no previous documentation of ASCVD. In the United States of America (USA), it is estimated that 50% of men and 64% of women who died of sudden cardiac death did not have a previous manifestation of atherosclerosis, and most were not considered high risk by the Framingham score [3]. These catastrophic outcomes occur despite atherosclerosis being a highly chronic, progressive disease that begins early in life and includes a prolonged subclinical phase, offering ample opportunity for detection and prevention [4,5]. Thus, the first episode of unstable angina, infarction, or stroke may represent an advanced stage of missed disease due to a lack of accessible screening tools and investments in primary prevention.

It is established that subclinical atherosclerosis can be detected using imaging biomarkers like carotid ultrasound. A focused, carotid ultrasound protocol that detects plaque presence is well-suited for screening ASCVD, as it can be performed in-office, is easy to learn, and is accompanied by an extensive body of evidence showing that carotid plaque correlates with outcomes [6–16]. Yet, screening for carotid plaque is not currently included in Canadian guidelines, in part due to a lack of evidence demonstrating the reliability and translation of such technology into primary prevention [17]. European guidelines support selective screening in high-risk subgroups where there is a higher prevalence of >70% asymptomatic carotid stenosis. However, these have not yet recommended population-wide screening for asymptomatic carotid stenosis due to its low prevalence and lack of evidence towards reducing CV risk [18]. Similarly, the US Preventive Services Task Force does not currently recommend screening for asymptomatic carotid stenosis in the general adult population [19].

Treatment with statins is equivocal in asymptomatic patients for primary prevention if low-density lipoprotein cholesterol (LDL-C) is ≥2 mmol/L but <3.5 mmol/L, as per the Canadian Cardiovascular Society (CCS) lipid guidelines [17]. Within this grey area, the guidelines suggest that if carotid atherosclerosis is detected, then this places the patient at higher risk and statins are recommended. The inherent contradiction is that such a simple, inexpensive test, which robustly predicts disease and could identify potentially missed higher-risk patients, is not yet incorporated on a routine basis.

Carotid ultrasound directly visualizes an individual’s atherosclerotic burden, transforming an abstract estimate into a tangible finding that can change both prescribing and patient adherence behaviour, as shown by the “Visualization of asymptomatic atherosclerotic disease for optimum CV prevention” (VIPVIZA) trial [20–22]. The problem for the VIPVIZA trial and other visualization trials has been the need for centralized imaging infrastructure, which limits atherosclerosis evaluation as a scalable screening strategy. 

Technological advancements have led to the miniaturization of ultrasound devices into compact, even handheld sizes, as well as lower device costs. Together, these developments have made it feasible for physicians to perform real-time, bedside assessments using ultrasound—a practice known as point of care ultrasound (POCUS) [23]. We have demonstrated good correlation between POCUS and conventional ultrasound for detecting plaque, even with complex measurements like plaque height and total plaque area [12]. We have also taught emergency department physicians to perform carotid POCUS in patients presenting with chest pain and showed a correlation with outcomes [6]. This tool could thus complement current risk stratification tools such as the Framingham risk score (FRS) [24] and the Primary Care Through Evidence and Education (PEER) score [25], which estimates a 10-year cardiovascular (CV) disease risk. We have recently demonstrated that a simple carotid plaque score can predict 10-year risk for major adverse CV events (MACE) in intermediate-risk patients [15].

POCUS is an emergent technology set to become the next stethoscope in primary care, with several family medicine programs across Canada calling for further training and uptake [26,27]. The development of continuing medical education (CME) training modules for POCUS provides clinicians with essential skills for real-time diagnostic bedside imaging. In the USA, POCUS has increased in family medicine residencies, with 53% of program directors reporting an established core curriculum [29]. The American Academy of Family Physicians (AAFP) has also published guidelines for residents, while organizations like the American College of Physicians (ACP) provide tailored POCUS pathways for internal medicine. Carotid POCUS training empowers primary care physicians to initiate the first stages of specialized care to facilitate referrals to cardiology. The widespread applications of POCUS hold promise not only for informing CV risk assessment procedures but also for offering tangible support to issues plaguing our primary healthcare system.

The purpose of this study was to determine the feasibility of implementing a focused carotid POCUS protocol into primary care practice to assess the presence of ASCVD in low-intermediate risk, asymptomatic patients.

Methods

Study Design

This study was a prospective two-site clinical study, testing the feasibility of integrating carotid POCUS in primary care by non-traditional POCUS users. Carotid POCUS represented a novel imaging biomarker not traditionally used in primary care in community clinics. A rapid, simple and easy-to-learn POCUS protocol was developed to detect carotid atherosclerosis in asymptomatic patients.

Participating Health Care Providers

Primary HCPs (physicians or nurses) from two local community clinics were approached using a pre-approved poster/email to participate in the study. Once enrolled and consent was gained, they were trained in carotid POCUS and plaque scoring via a web-based learning module (www.arcticapocus.com) and through a 1-hour expert-led hands-on workshop. ARCTICA Module 4: Carotid POCUS is now certified for up to two MAINPRO+ credits for Family Medicine Specialists and accredited for up to two hours of MOC Section Three Self-Assessment credits for Royal College Specialists. Following training, HCPs scanned and scored eligible patients from their respective clinics. Physician competency was assessed by comparing their plaque scoring to that of a vascular imaging expert. The selected expert was a vascular researcher with >10 years of experience in carotid ultrasound image analysis. Feedback on images and scores was provided for the first few patients. The ensuing change in physician behaviour (pre- and post-carotid POCUS) regarding the level of CV risk (low, moderate, high) of their patient and treatment strategy was evaluated in response to carotid POCUS by questionnaire. Questions (Supplementary Material – Appendix S1) included: Risk Perception – What was your baseline risk assessment for the patient?  (Low, Intermediate, High); Does the use of carotid POCUS change your risk assessment of this patient? (Yes, No; If yes, Increased or Decreased).

Sample Patient Population

Consecutive outpatients attending their primary care clinic visit meeting the inclusion criteria received a carotid POCUS using a focused vascular ultrasound protocol to image the three carotid segments. The inclusion criteria included: 1) Males and females ≥40 years; 2) Referred to a primary care community clinic for risk assessment and having one or more cardiac risk factors: BMI ≥30 kg/m2, diabetes or elevated fasting glucose (5.6 mmol/L (100 mg/dL), HbA1c ≥6.2%), hypertension (elevated blood pressure: systolic >130 and/or diastolic >85 mmHg or treated), current smoker (tobacco), elevated triglycerides: 1.7 mmol/L (150 mg/dL), reduced high-density lipoprotein cholesterol (HDL-C): 1.0 mmol/L (40 mg/dL) in males, 1.3 mmol/L 50 mg/dL in females, or  LDL-C ≥2 mmol/L; 3) Able and willing to give informed consent. The exclusion criteria were statin usage within the last 12 months, history of stroke, history of myocardial infarction (MI), history of significant coronary artery disease (percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), or coronary angioplasty), contradiction to statins (known or documented hypersensitivity or allergy), and any condition expected to limit survival <3 years, a condition expected to limit adherence (alcoholism, addiction, or known poor adherence), or previous enrolment in the study.

Each HCP required a minimum of 15 patients. Baseline clinical variables such as patient demographics and comorbidities were collected by patient interviews and medical chart reviews. Study data were collected and managed using REDCap electronic data capture tools hosted at Queen’s University [30,31].

Follow-up for Cardiovascular Outcomes and Medication Adherence

Patient participants were followed for up to 1-year by telephone and medical chart review. Information collected included: changes in medications, lifestyle changes (smoking cessation, diet, and exercise), CV testing (stress test, computed tomography-angio, coronary angiogram), ASCVD-related hospitalization, cardiology referrals, and MACE (all-cause mortality, myocardial infarction, unstable angina, stroke, transient ischemic attack, and coronary revascularization – PCI and CABG). If the participant was prescribed a statin medication, the Morisky Medication Adherence Scale (MMAS-8) scoring questionnaire was given to determine medication adherence (permission obtained) [32]. The MMAS-8 total score ranges from 0 to 8. The general interpretation was for High Adherence: Score of 8, Medium Adherence: Score of 6 to <8, and Low Adherence: Score <6 [32].

Carotid POCUS

For each patient participant, a focused carotid ultrasound of the common carotid artery (CCA), bulb, and internal carotid artery (ICA) was performed by the primary care provider. Images were taken using a Vscan Extend™ Handheld Ultrasound (GE Healthcare Canada, Mississauga, ON, Canada) with a linear array transducer (3.3–8.0 MHz).

Plaque scores were determined using the Rotterdam method (demonstrated in Figure 1) and noted on a worksheet (Supplementary Material – Appendix S1) [7,15,16,33]. In brief, the minimal score was 0, and the maximal score is 6. If plaque was present in 2 or more of the 6 carotid segments (left or right CCA, bulb, ICA), this represented a plaque score ≥2, which correlated to an increased risk for 10-year MACE [15]. Clinically significant carotid plaque was defined as having a minimum plaque height of ≥1.5mm (Grade II) [11].

Figure 1. Carotid POCUS Plaque Score Protocol. Staring on the left side, (A) perform a short-axis sweep of the carotid artery starting at the common carotid artery (CCA), moving towards the bulb/bifurcation and following the internal carotid artery (ICA) to identify any presence of plaque; capture the cine loop video (last 4 seconds of acquisition). (B) Changing the orientation of the transducer to the long-axis, acquire a still image of the CCA and (C) the bulb/ICA. If plaque is identified in any of the three segments (CCA, ICA, bulb), one point is assigned per segment (the external carotid artery, ECA, is not taken into consideration in the score). Repeat on the right side (D) short axis sweep video, (E) CCA still image, and (F) bulb/ICA still image. Assign one point per segment if plaque is present. The sum of the plaque scores for the two sides gives the patient the total plaque score (a minimum of zero, if there is no plaque, to a maximum of 6, if plaque is present in all segments). The patient in this figure has a total plaque score of 1. The yellow arrow points to a plaque present in the bulb.

General Protocol

Start with the left side. Perform a short-axis sweep of the carotid artery, starting at the CCA, moving towards the bulb/bifurcation, and following the ICA to assess for the presence of plaque. Save/store the video clip with the transducer indicator pointed toward the patient’s right side. Next, rotate the transducer (indicator pointed to the patient’s head) to obtain long-axis views. Assess the three segments (CCA, ICA, and bulb; excluding the ECA) for plaque, and pause to store the images. Assign one point to each segment containing plaque, regardless of wall location or the number of plaques. Sum the points to calculate the plaque score for the left side.

Repeat the procedure on the right side. The total plaque score is the sum of the left and right-sided scores (range 0 to 6).

If there is uncertainty in distinguishing plaque or Carotid Intima-Media Thickness (CIMT), use callipers to measure the height from the adventitia to the top of the protrusion into the lumen. Plaque is defined as a thickness that is ≥1.5 mm.

Statistical Analyses

All statistical analyses were performed using JMP version 18.0 (JMP Statistical Discovery LLC, Cary, NC, USA). The Fisher’s exact test (two-tailed) was used to compare nominal variables, and two-sample t tests (two-tailed, unequal variances) were used for continuous variables. To assess the competence of HCPs in determining plaque score using carotid POCUS, scans were reviewed by an imaging expert. The Shrout-Fleiss correlation was used to assess the reliability of agreement (intraclass correlation coefficient, ICC) between HCPs and the expert in plaque score. To evaluate whether POCUS application changed physician behaviour in the treatment plan, a change in risk assessment of their patient was quantified (no change, increased, or decreased). Statistical significance was accepted at α <0.05.

Results

Patient Participant Baseline Characteristics

A total of 77 patient participants were enrolled and received a carotid POCUS between November 17, 2023, and February 12, 2026. The mean age of the study cohort was 59.6 ± 10.2 years old and there were 55 females and 22 males (Table 1). The main cardiac risk factors included hypertension (35.1%), hyperlipidemia (15.6%), and smoking (16.7%). 

Table 1. Study sample baseline characteristics.
VariableAllFemaleMaleP-Value
(N = 77)(N = 55)(N = 22)
Age (years), mean ± SD59.6 ± 10.259.7 ± 10.159.1 ± 10.50.82
BMI (kg/m^2), mean ± SD31.5 ± 11.332.6 ± 12.828.7 ± 4.350.07
LDL (mmol/L), mean ± SD3.08 ± 0.763.06 ± 0.803.15 ± 0.630.66
HDL (mmol/L), mean ± SD1.53 ± 0.461.59 ± 0.481.36 ± 0.360.06
Total Cholesterol (mmol/L), mean ± SD5.19 ± 1.015.20 ± 0.995.15 ± 1.110.89
Glucose (mmol/L), mean ± SD5.32 ± 0.435.31 ± 0.545.33 ± 0.240.92
eGFR (mL/min/1.73), mean ± SD84.0 ± 18.183.6 ± 18.485.0 ± 17.90.79
FRS (%), mean ± SD11.4 ± 8.128.26 ± 5.0821.3 ± 8.170.0001
PEER (%), mean ± SD11.5 ± 9.497.96 ± 4.9022.8 ± 11.70.0001
Diabetes, n (%)3 (3.90)2 (3.64)1 (4.55)1
Hypertension, n (%)27 (35.1)14 (25.6)13 (59.1)0.008
Hyperlipidemia, n (%)12 (15.6)10 (18.2)2 (9.09)0.49
Current Smoker, n (%)13 (16.9)6 (10.9)7 (31.8)0.04
Cardiac Medications
ACE Inhibitors, n (%)11 (14.3)5 (9.09)6 (27.3)0.07
ARBs Angiotensin, n (%)9 (11.7)7 (12.7)2 (9.09)1
Alpha-Blockers, n (%)2 (2.60)02 (9.09)0.08
Beta-Blockers, n (%)15 (19.5)9 (16.4)6 (27.3)0.34
Calcium Channel Blockers, n (%)15 (19.5)8 (14.6)7 (31.8)0.11
Anti-Platelet/Anti-Coagulation, n (%)12 (15.6)8 (14.6)4 (18.2)0.73
NSAIDS, n (%)4(2.19)2 (3.64)2 (9.09)0.57
Anti-Anginal, n (%)2 (2.60)1 (1.82)1 (4.55)0.49
Diuretics, n (%)12 (15.6)9 (16.4)3 (13.6)1
Non-Insulin Diabetes Medication, n (%)7 (9.09)6 (10.9)1 (4.55)0.67
ARB, angiotensin II receptor blockers; ACE, angiotensin-converting enzyme inhibitors; BMI, body mass index; eGFR, estimated glomerular filtration rate; FRS, Framingham risk score; NSAIDS, non-steroidal anti-inflammatory drugs; PEER, primary care through evidence and education.

Some sex differences were observed in the sample population (Table 1). Compared to females, males were more likely to have hypertension (59.1% vs 25.6%; p = 0.008) and be current smokers (31.8% vs 10.9%; p = 0.04). Among participants with complete data for FRS calculation (n = 50), the mean FRS was lower in females (8.26 ± 5.08) compared to males (21.3 ± 8.17; p = 0.0001) [24]. A similar pattern was observed for the PEER score [25].

Carotid POCUS Intraclass Correlation Coefficient of Health Care Providers compared to Expert

Five HCPs, two nurses, and three family physicians were enrolled from two community clinics. HCPs completed a 45-minute web-based learning module and quiz assessment, with a requirement of an 85% grade to pass the module. A 1-hour hands-on workshop was also held, where each HCP was able to learn how to operate the POCUS device and given the opportunity to perform a carotid ultrasound on a volunteer under the guidance of an expert.

After training, HCPs performed 15–17 carotid scans and scored the plaque. POCUS was performed within the workflow of the clinic. The average scan time was 7.00 ± 3.51 minutes. Images were reviewed and scored separately by a vascular imaging expert. To assess the HCP accuracy in performing the POCUS exam and assigning a plaque score, the HCP plaque score and the expert plaque score were compared. The average ICC was 0.764 (Table 2), which corresponded to good agreement (good reliability).

Table 2. Intraclass correlation coefficient of health care providers compared to an expert.
Healthcare ProviderN (POCUS scans)ICCInterpretationBias and Interactions ImpactLower 95% CI
1170.786Good agreement0.210.57
2150.709Moderate agreement0.290.42
3150.714Moderate agreement0.280.43
4150.841Good agreement0.160.68
5150.772Good agreement0.230.54
All770.764Good agreement0.230.53
HCP, health care provider; CI, confidence interval; ICC, intraclass correlation coefficient.

Among the 77 patient participants imaged, 26 (35%) had a plaque score ≥2, deemed higher risk for 10-year MACE (Table 3). Males were more likely to have a plaque score ≥2 compared to females (54.6% vs 25.5%; p = 0.02). Females were more likely to have a plaque score = 0, compared to males (47.3% vs 18.2%; p = 0.02). The FRS and PEER scores were plotted against plaque score to determine correlations. Plaque score increased with FRS (p = 0.001) and PEER scores (P<0.0001) (Figure 2).

Table 3. Plaque scores of the study population.
Plaque ScoreAllFemale Male P-Value
(N = 77)(N = 55)(N = 22)
Plaque score = 0, n (%)30 (39.0)26 (47.3)4 (18.2)0.02
Plaque score = 1, n (%)21 (27.3)15 (27.3)6 (27.3)1
Plaque score = 2, n (%)18 (23.4)(10 (18.2)8 (36.4)0.13
Plaque score = 3, n (%)5 (6.49)3 (5.45)2 (9.09)0.62
Plaque score = 4, n (%)000N/A
Plaque score = 5, n (%)3 (3.90)1 (1.82)2 (9.09)0.19
Plaque score = 6, n (%)000N/A
Plaque score <2, n (%)51 (66.2)41 (74.6)10 (45.5)0.02
Plaque score ≥2, n (%)26 (33.8)14 (25.5)12 (54.6)0.02
Figure 2. Box plot of plaque score in relation to traditional cardiovascular risk stratification tools. (A) Framingham Risk Score and (B) Primary Care Through Evidence and Education (PEER) score. Plaque score increased with traditional cardiovascular risk scores. Means were compared using one-way ANOVA.

Change in Treating Physician Behaviour Following Carotid POCUS

After performing patient scans, treating physicians were asked to complete a questionnaire to determine whether the carotid POCUS results changed their CV risk assessment of their patient. For the HCPs who were nurses, the PCUS plaque score was sent to the treating physician. For the HCP family physicians, these were their own patients. Changes in physician behaviour were noted for 27 patients (35%), triggering statin treatment initiation. From these, the addition of POCUS resulted in an increase in baseline CV event risk assessment in 20 patients and a decrease in baseline CV event risk assessment in 7 patients. Statin treatment was initiated by 16 patients (Table 4); 7 with a plaque score <2 (likely due to the presence of CV risk factors, cholesterol levels, or plaque score = 1) and 9 with a plaque score ≥2. Fourteen participants answered the MMAS-8 questionnaire [32]. The average score was 7.35, indicating medium to high adherence. Eight participants had a score of 8 (high adherence, 62%), 4 participants had a score of 6 to <8 (medium adherence, 29%), and only 1 had a score <6 (low adherence, 8%).

Table 4. Patient risk reclassification.
Plaque Score <2
N (All)Risk Change? N Statin (Initiated)
Baseline CV risk No ChangeStatin (Initiated)DecreasedStatin (Initiated)IncreasedStatin (Initiated)
Unknown107130001
Low3023100712
Intermediate96120112
High22200002
Sum5138550827
Plaque Score ≥2
N (All)Risk Change?N Statin (Initiated)
Baseline CV risk No ChangeStatin (Initiated)DecreasedStatin (Initiated)IncreasedStatin (Initiated)
Unknown86200224
Low50000533
Intermediate104220402
High32000100
Sum26124201259
All775097020716
CV, cardiovascular.

Follow-up for MACE

Patient participants were followed up to 1-year for MACE (Death, MI, Unstable Angina, PCI, CABG, Stroke, TIA). No MACE occurred during follow-up. Three participants received an angiogram but were found to have no or mild coronary artery disease. Thirteen participants were diagnosed with hyperlipidemia, and two with hypertension. One participant was referred to a formal carotid ultrasound; carotid plaques were identified bilaterally.

HCP Feedback:

Following our pilot study, we conducted a stakeholder group feedback session to assess the impact on clinical burden. The feedback was overwhelmingly positive: POCUS added minimal additional time to the physical exam vascular check, as there was no archiving or formal reporting beyond brief documentation in physical exam notes. HCPs were strongly in favour of continuing to use the tool, as the absence of having this information for risk assessment was a glaring clinical gap. The tool helped reduce decision time and simplified practice by reducing the need to bring borderline patients back for repeated clinic visits and counselling to decide whether statins should begin. In certain cases, when plaque was present, the physician and patient were motivated to follow guidelines (start treatment when previously undecided).

Discussion

In this prospective pilot study, we demonstrated that primary HCPs can be successfully trained to perform focused carotid POCUS to detect subclinical atherosclerosis, with good agreement compared to an expert reader. Following a brief training program, HCPs achieved good reliability in plaque scoring using the Rotterdam method. The incorporation of carotid POCUS into routine primary care visits further influenced physician risk assessment and management decisions in a significant proportion of patients. Together, these findings support the feasibility of implementing carotid POCUS as a vascular risk stratification tool in primary care settings.

A key finding of this study was the strong agreement between HCP–assigned plaque scores and expert interpretation, reflected by an average ICC of 0.764, consistent with good reliability. This level of agreement is notable given the short duration of training and the fact that participants included non-traditional ultrasound users. These findings align with prior work that demonstrated focused vascular ultrasound protocols can be learned rapidly and applied reliably by non-experts, particularly when the protocol emphasizes binary plaque detection rather than more complex measurements such as total plaque area [6,15,16]. Our results extend this literature by demonstrating that carotid POCUS can be implemented successfully in community primary care clinics, rather than academic or emergency department environments.

The detection of carotid plaque score ≥2 in 34% of this asymptomatic (61% with the presence of some plaque, plaque score ≥1), low-to-intermediate risk population highlight the limitations of traditional CV risk scoring tools. Numerous studies have shown that carotid plaque is a strong and independent predictor of MI and stroke, often outperforming conventional risk scores [7–9,14,16]. Visualization of carotid POCUS at the bedside affects both patient and physician adherence to guideline-directed therapy [34,35]. The presence of plaque represents silent disease and may provide a more intuitive and actionable signal for both clinicians and patients. In this study, visualization of plaque directly influenced physician behaviour, with reclassification of CV risk and the initiation of statin therapy in a subset of patients. Importantly, management changes not only resulted in detecting increased risk; in some cases, POCUS findings lowered baseline risk assessment of the patient, suggesting that carotid POCUS may also help avoid unnecessary treatment. High adherence to statin therapy was observed in 62% of patients prescribed statins, indicating a need for improved education. It is important to note that a negative POCUS does not replace CV risk factor assessment and cholesterol findings but may help provide additional information on the vascular health of the patient. Additional work to assess MACE in a larger population is needed to establish test characteristics.

These findings are particularly relevant in the context of current CV prevention guidelines, which do not recommend routine carotid imaging for screening, in part due to concerns regarding access, cost, and feasibility [17]. POCUS has the potential to address these barriers by offering a rapid, low-cost, radiation-free imaging modality that can be performed at the point-of-care without reliance on centralized imaging infrastructure. As POCUS ultrasound devices become increasingly affordable and accepted (handheld, laptop, tablet, etc.), carotid POCUS may represent an important step in operationalizing imaging-based risk assessment within primary prevention frameworks.

Beyond its diagnostic utility, carotid POCUS may also offer important system-level benefits. Primary care physicians in Canada have identified limited access to diagnostics and outdated technology as major impediments to delivering high-quality preventive care [28]. Integrating carotid POCUS into primary care practice may streamline risk assessment, reduce downstream referrals for diagnostic imaging, and facilitate earlier engagement with preventive therapies. Moreover, visualizing atherosclerosis at the bedside may enhance patient understanding of CV risk and support shared decision-making, although this was not directly assessed in the present study.

Limitations

Some limitations should be acknowledged due to the small sample size. As this was a small pilot study with a limited number of HCPs and patients, it was not powered to assess clinical outcomes. No major adverse CV events were observed during the follow-up period, which was expected given the modest sample size and relatively short follow-up duration. The study did not include a formal comparison with standard risk calculators or conventional carotid ultrasound performed in accredited vascular laboratories. No official competency grading of the HCP was performed for image acquisitions. Scanning was not repeated by the HCP or the expert. Long-term retention of scanning competency and scalability of training were not evaluated. Finally, it is possible that the HCPs involved in this study may have had a greater interest in this kind of approach and hence may have been more engaged in training than a non-select HCP population. 

Despite these limitations, this study provides important proof-of-concept evidence supporting the feasibility, reliability, and clinical impact of carotid POCUS in primary care. Future larger, multicentre studies are warranted to evaluate long-term outcomes, cost-effectiveness, patient-centred benefits, and optimal training and quality assurance frameworks. Establishing standardized guidelines for vascular POCUS use by non-traditional ultrasound users will be critical to ensuring safe and effective implementation.

Conclusion

Focused carotid POCUS can be reliably performed by trained primary HCPs and has the potential to meaningfully influence CV risk assessment and preventive management. By enabling direct visualization of subclinical atherosclerosis at the point-of-care, carotid POCUS represents a promising tool to modernize primary prevention strategies and advance personalized CV care.

Acknowledgements

The authors would like to thank the participating primary care clinics and healthcare providers for their time, enthusiasm, and commitment to integrating carotid point of care ultrasound into routine practice. We are grateful to the patients who volunteered to participate in this study. We also acknowledge the support the clinical and administrative staff at the participating sites for their assistance with study implementation and patient screening. MMAS® 2006 used with permission www.moriskyscale.com.

Ethics Statement

Informed consent was obtained from all participants (healthcare providers (HCPs) and patients) in this study for carotid POCUS and the use of data for publication. This study conforms to the ethical guidelines of the 1975 Declaration of Helsinki. This study was approved by Queen’s University Health Sciences and Affiliated Teaching Hospitals Research Ethics Board (DMED-2735-23).

Disclosure Statement

The authors declare that they have no competing interests or conflicts of interest relevant to this work.

Funding

This study was supported by a grant from the Queen’s University Translational Institute of Medicine and University Hospitals Kingston Foundation fund (TIME-UHKF Incubator Grant to AMJ) as well as a grant from the Queen’s University Faculty of Health Sciences Garfield Kelly fund (to AMJ). POCUS devices were purchased using donation funds through the University Hospitals Kingston Foundation.

Author Contributions

MFH: study conceptualization, methodology, formal analysis, data curation, project administration, and drafting of the manuscript. TB: manuscript drafting, study implementation, coordination, participant enrollment, data collection, and data curation. AP: study implementation, coordination, participant enrollment, data collection, and data curation. NA: design and development of the carotid POCUS teaching module. TZ, MC, SCH, IT and SW: study implementation, participant screening, carotid POCUS examinations, and manuscript review and editing. TS: design, implementation, and data collection of the medication adherence component. UN: manuscript writing, review and editing. AMJ: conceived and supervised the study, secured funding, and contributed to the study conceptualization, methodology, and manuscript review and editing. All authors reviewed and approved the final manuscript.

References

1. WHO. Cardiovascular diseases (CVDs) fact sheet. 2021

2. WHO. Global burden of disease collaborative network, global burden of disease study 2019. Institute for Health Metrics and Evaluation – IHME 2022

3. Gatto L, Prati F. Subclinical atherosclerosis: how and when to treat it? Eur Heart J Suppl. 2020;22:E87-E90. doi:10.1093/eurheartj/suaa068

4. Almohtasib Y, Fancher AJ, Sawalha K. Emerging Trends in Atherosclerosis: Time to Address Atherosclerosis From a Younger Age. Cureus. 2024;16:e56635. doi:10.7759/cureus.56635

5. Raitakari O, Pahkala K, Magnussen CG. Prevention of atherosclerosis from childhood. Nat Rev Cardiol. 2022;19:543-554. doi:10.1038/s41569-021-00647-9

6. Brooks SC, Sivilotti MLA, Hétu MF, Norman PA, Day AG, O’Callaghan N, Latiu V, Newbigging J, Hill B, Johri AM. Focused carotid ultrasound to predict major adverse cardiac events among emergency department patients with chest pain. CJEM. 2023;25(1):81-89. doi: 10.1007/s43678-022-00395-w

7. Hollander M, Bots ML, Del Sol AI, Koudstaal PJ, Witteman JC, Grobbee DE, Hofman A, Breteler MM. Carotid plaques increase the risk of stroke and subtypes of cerebral infarction in asymptomatic elderly: the Rotterdam study. Circulation. 2002;105(24):2872-7. doi: 10.1161/01.cir.0000018650.58984.75

8. Inaba Y, Chen JA, Bergmann SR. Carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events: a meta-analysis. Atherosclerosis. 2012;220:128-33. doi:10.1016/j.atherosclerosis.2011.06.044

9. Johnsen SH, Mathiesen EB, Joakimsen O, Stensland E, Wilsgaard T, Løchen ML, Njølstad I, Arnesen E. Carotid atherosclerosis is a stronger predictor of myocardial infarction in women than in men: a 6-year follow-up study of 6226 persons: the Tromsø Study. Stroke. 2007;38(11):2873-80. doi: 10.1161/STROKEAHA.107.487264

10. Johri AM, Calnan CM, Matangi MF, MacHaalany J, Hetu MF. Focused Vascular Ultrasound for the Assessment of Atherosclerosis: A Proof-of-Concept Study. J Am Soc Echocardiogr. 2016;29:842-9. doi:10.1016/j.echo.2016.05.003

11. Johri AM, Nambi V, Naqvi TZ, Feinstein SB, Kim ESH, Park MM, Becher H, Sillesen H. Recommendations for the Assessment of Carotid Arterial Plaque by Ultrasound for the Characterization of Atherosclerosis and Evaluation of Cardiovascular Risk: From the American Society of Echocardiography. J Am Soc Echocardiogr. 2020;33(8):917-933. doi: 10.1016/j.echo.2020.04.021

12. Mantella LE, Colledanchise K, Bullen M, Hétu MF, Day AG, McLellan CS, Johri AM. Handheld versus conventional vascular ultrasound for assessing carotid artery plaque. Int J Cardiol. 2019;278:295-299. doi: 10.1016/j.ijcard.2018.12.014

13. Roifman I, Wijeysundera HC, Austin PC, Rezai MR, Wright GA, Tu JV. Comparison of Anatomic and Clinical Outcomes in Patients Undergoing Alternative Initial Noninvasive Testing Strategies for the Diagnosis of Stable Coronary Artery Disease. J Am Heart Assoc. 2017;6. doi:10.1161/JAHA.116.005462

14. Sposato LA, Lam M, Allen B, Shariff SZ, Saposnik G, Group PS. First-Ever Ischemic Stroke and Incident Major Adverse Cardiovascular Events in 93 627 Older Women and Men. Stroke. 2020;51:387-394. doi:10.1161/STROKEAHA.119.028066

15. Matangi MF, Hétu MF, Armstrong DWJ, Shellenberger J, Brouillard D, Baker J, Johnson A, Grubic N, Willms H, Johri AM. Carotid plaque score is associated with 10-year major adverse cardiovascular events in low-intermediate risk patients referred to a general cardiology community clinic. Eur Heart J Cardiovasc Imaging. 2025;26(4):714-724. doi: 10.1093/ehjci/jeae153

16. Matangi MF, Hétu MF, Armstrong DWJ, Shellenberger J, Brouillard D, Baker J, Johnson A, Willms H, Johri AM. ICEBERG-3: carotid plaque score combined with the stress echo improves 5-year major adverse cardiovascular events risk prediction. Eur Heart J Open. 2025;5(3):oeaf065. doi: 10.1093/ehjopen/oeaf065

17. Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, Francis GA, Genest J, Grégoire J, Grover SA, Gupta M, Hegele RA, Lau D, Leiter LA, Leung AA, Lonn E, Mancini GBJ, Manjoo P, McPherson R, Ngui D, Piché ME, Poirier P, Sievenpiper J, Stone J, Ward R, Wray W. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Can J Cardiol. 2021;37:1129-1150. doi:10.1016/j.cjca.2021.03.016

18. Paraskevas KI, Musialek P, Lip GYH, Chaturvedi S. Selective Screening for Asymptomatic Carotid Artery Stenosis: An Appraisal of the 2024 European Society of Cardiology (ESC) Guidelines Position. Am J Med. 2025;138:209-211. doi:10.1016/j.amjmed.2024.10.033

19. US Preventive Services Task Force; Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, Caughey AB, Donahue K, Doubeni CA, Epling JW Jr, Kubik M, Ogedegbe G, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for Asymptomatic Carotid Artery Stenosis: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(5):476-481. doi: 10.1001/jama.2020.26988

20. Kebric A, Petek Ster M, Poljansek Avsenak A, Jug B. Point-of-care ultrasonography of carotid arteries in primary care: sensitivity and specificity of identification of carotid atherosclerosis and prevalence of carotid atherosclerosis in apparently healthy subjects with high and very high cardiovascular disease risk. BMC Prim Care. 2025;26:244. doi:10.1186/s12875-025-02945-4

21. Chang WL, Chen PY, Hsu PJ, Lin SK. Validity and Reliability of Point-of-Care Ultrasound for Detecting Moderate- or High-Grade Carotid Atherosclerosis in an Outpatient Department. Diagnostics (Basel). 2023;13. doi:10.3390/diagnostics13111952

22. Näslund U, Ng N, Lundgren A, Fhärm E, Grönlund C, Johansson H, Lindahl B, Lindahl B, Lindvall K, Nilsson SK, Nordin M, Nordin S, Nyman E, Rocklöv J, Vanoli D, Weinehall L, Wennberg P, Wester P, Norberg M; VIPVIZA trial group. Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trial. Lancet. 2019;393(10167):133-142. doi: 10.1016/S0140-6736(18)32818-6

23. Shen-Wagner J, Deutchman M. Point-of-Care Ultrasound: A Practical Guide for Primary Care. Fam Pract Manag. 2020;27:33-40

24. D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-53. doi: 10.1161/CIRCULATIONAHA.107.699579

25. Kolber MR, Klarenbach S, Cauchon M, Cotterill M, Regier L, Marceau RD, Duggan N, Whitley R, Halme AS, Poshtar T, Allan GM, Korownyk CS, Ton J, Froentjes L, Moe SS, Perry D, Thomas BS, McCormack JP, Falk J, Dugré N, Garrison SR, Kirkwood JEM, Young J, Braschi É, Paige A, Potter J, Weresch J, Lindblad AJ. PEER simplified lipid guideline 2023 update: Prevention and management of cardiovascular disease in primary care. Can Fam Physician. 2023;69(10):675-686. doi: 10.46747/cfp.6910675

26. Micks T, Braganza D, Peng S, McCarthy P, Sue K, Doran P, Hall J, Holman H, O’Keefe D, Rogers P, Steinmetz P. Canadian national survey of point-of-care ultrasound training in family medicine residency programs. Can Fam Physician. 2018;64(10):e462-e467

27. Peng S, Micks T, Braganza D, Sue K, Woo M, Rogers P, Freedman S, Lewis J, Hu S, Varner C, Patel N, Hameed S, Steinmetz P. Canadian national survey of family medicine residents on point-of-care ultrasound training. Can Fam Physician. 2019;65(12):e523-e530

28. CFPC. Transforming the Foundation of Canada’s Health Care System – Solutions to bolster primary care. Mississauga, ON: College of Family Physicians of Canada, 2023

29. Hall JWW, Holman H, Barreto TW, Bornemann P, Vaughan A, Bennett KJ, Chamberlain J, Micks T, Maurer DM, Bergus GR. Point-of-Care Ultrasound in Family Medicine Residencies 5-Year Update: A CERA Study. Fam Med. 2020;52(7):505-511. doi: 10.22454/FamMed.2020.223648

30. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN; REDCap Consortium. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95:103208. doi: 10.1016/j.jbi.2019.103208

31. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377-81. doi:10.1016/j.jbi.2008.08.010

32. Krousel-Wood M, Islam T, Webber LS, Re RN, Morisky DE, Muntner P. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care. 2009;15:59-66.

33. van der Meer IM, Bots ML, Hofman A, del Sol AI, van der Kuip DA, Witteman JC. Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation.2004;109:1089-94. doi:10.1161/01.CIR.0000120708.59903.1B

34. Korcarz CE, DeCara JM, Hirsch AT, Mohler ER, Pogue B, Postley J, Tzou WS, Stein JH. Ultrasound detection of increased carotid intima-media thickness and carotid plaque in an office practice setting: does it affect physician behavior or patient motivation? J Am Soc Echocardiogr. 2008;21(10):1156-62. doi: 10.1016/j.echo.2008.05.001

35. Wyman RA, Gimelli G, McBride PE, Korcarz CE, Stein JH. Does detection of carotid plaque affect physician behavior or motivate patients? Am Heart J. 2007;154:1072-7. doi:10.1016/j.ahj.2007.06.046

Posted in .

Leave a Reply

Your email address will not be published. Required fields are marked *